WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) issued a guidance for industry that describes how firms can voluntarily engage with the FDA before marketing food from genome-edited plants.
The guidance reaffirms that the risk-based approach the FDA has taken for foods derived from new plant varieties also applies to foods from genome-edited plants. In addition, it describes two processes through which developers may voluntarily inform the FDA of the steps they have taken to ensure the safety of foods from their genome-edited plant varieties: voluntary premarket consultations and voluntary premarket meetings. These processes can help ease the pathway to market for foods from genome-edited plants while keeping FDA safeguards in place, said FDA.
Read the full guidance here.
Get curated news on YOUR industry.
Enter your email to receive our newsletters.Latest from Quality Assurance & Food Safety
- Q&A: Sandra Eskin Leads Food Safety Advocacy Organization, STOP, as CEO
- STOP CEO Eskin on Government Layoffs, Challenges in Food Safety
- Mission Barns Announces Cell-Cultivated Pork Fat Launch Following FDA Clearance
- Hearthside Food Solutions Recalls Breakfast Sandwiches Due to Undeclared Allergen
- Walker’s Wine Juice Recalls Pumpkin Juice Due to Botulism Risk
- The Cascading Food Safety Impacts of Tariffs on the Food Industry
- Tyson Ventures Calls Startups to Apply for Tyson Demo Day
- Student Finalists Selected for IFT Product Development Competitions
